Advertisement
DHR vs TMO
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Danaher (DHR) recently reported Q1 adjusted EPS (earnings per share) of $2.06, beating estimates, though revenue missed at $5.95 billion, leading to a post-earnings dip.
- TMO shows stronger recent monthly gains of over 12%, with year-to-date return at 9.13% and one-year at 23.50%, outperforming DHR on longer-term metrics.
- Thermo Fisher boasts a lower trailing P/E ratio (price-to-earnings ratio) of 29.67 versus Danaher's 38.94, suggesting relatively cheaper valuation.
- Both operate in life sciences tools, but Danaher holds lower debt-to-equity at 37% compared to Thermo Fisher's 77%.
- Market caps differ notably: Thermo Fisher at $195 billion versus Danaher's $138 billion.
- Tickeron's AI tools highlight momentum favoring TMO amid recent market positioning.
Introduction
Danaher Corporation (DHR) and Thermo Fisher Scientific (TMO) are leading players in the life sciences and diagnostics sector, providing essential tools, instruments, and services for biotech research and healthcare. This stock comparison analyzes their recent performance, valuations, and market dynamics in the current environment. Traders seeking momentum plays and long-term investors evaluating growth stability in healthcare equipment will find value in understanding relative strengths, such as valuation multiples and sector catalysts. With both stocks sensitive to bioprocessing demand and economic cycles, insights into head-to-head metrics aid informed positioning.
DHR Overview and Recent Performance
Danaher Corporation (DHR) is a global conglomerate focused on life sciences, diagnostics, and environmental applied solutions, with key segments in bioprocessing, flow cytometry, and water quality products. In recent market activity, DHR stock trades around $195.50, with a market cap of $138 billion and 52-week range of $180-$243. Year-to-date gains stand at 14.42%, though one-year returns are modest at 5.36%. Recent weeks saw a revenue miss in Q1 at $5.95 billion despite adjusted EPS beat of $2.06, driven by bioprocessing strength but offset by softer diagnostics demand; this influenced a sentiment shift and price pullback. Broader trailing P/E (price-to-earnings ratio) is 38.94, with quarterly revenue growth at 4.6% year-over-year.
TMO Overview and Recent Performance
Thermo Fisher Scientific (TMO) specializes in life sciences solutions, including analytical instruments, reagents, and biopharma services, serving research, diagnostics, and applied markets. Currently trading near $526, with a $195 billion market cap and 52-week range of $385-$644, TMO has posted year-to-date returns of 9.13% and one-year gains of 23.50%. Recent momentum has been robust, with weekly gains over 5% and monthly advances exceeding 12%, bolstered by anticipation for Q1 earnings on April 23 projecting $10.83 billion revenue and $5.21 EPS. Sentiment remains positive amid analyst price target adjustments, supported by 7.2% quarterly revenue growth year-over-year and trailing P/E of 29.67.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top 25 AI trading bots from over 351 available, each designed for diverse strategies across thousands of tickers in stocks, ETFs, and crypto. These bots showcase impressive stats, including win rates from 54% to 88%, annualized returns ranging 15% to 168%, profit factors up to 11.7, and trade durations from 1 day to 55 days. Examples trade semiconductors like NVDA and AMD, leveraged ETFs such as SOXL/SOXS, or sector plays in energy and aerospace. Selected for current market suitability, they offer short-term scalping, swing trading, or long-term holds with profit-to-drawdown ratios up to 22. Traders can explore these high-performing, real-time adaptive bots to match their risk profile and timeframe.
Head-to-Head Comparison
Both DHR and TMO thrive in life sciences tools, but Danaher's diversified model spans diagnostics and environmental segments, contrasting Thermo Fisher's concentrated focus on instruments and services. Growth drivers include bioprocessing demand for both, though TMO edges with higher quarterly revenue growth at 7.2% versus 4.6%. Recent momentum favors TMO's 12% monthly rise over DHR's 0.6%, reflecting pre-earnings optimism versus post-earnings caution. Risk factors highlight Danaher's lower debt-to-equity (37% vs. 77%), aiding stability, while TMO's lower P/E offers value trade-offs. Sector exposure is similar in healthcare equipment, but market sentiment tilts toward TMO for relative performance in volatile conditions.
Tickeron AI Verdict
Tickeron’s AI currently favors TMO with higher probability due to consistent recent momentum, attractive valuation via lower P/E, and positive catalysts ahead of earnings, positioning it stronger relative to DHR's revenue pressures despite EPS resilience.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
DHR and TMO are companies in the life sciences and diagnostics sector of healthcare, but DHR has historically been more diversified in terms of the services it provides and industries. In recent years, it has separated itself from certain subsidiaries. The companies have been on a wild ride throughout the pandemic, with promising opportunities to play a role in the battle against the virus, but they have also shared in the uncertainty and struggles that other industries have been due to closures. Both have done extremely well in recent quarters providing life science products and solutions to the healthcare industry and governments. DHR made two extremely profitable acquisitions just prior to the pandemic that put it in a prime position for revenue growth; namely Cepheid, which has churned out Covid test kits, and Cytiva, which used to be GE’s biopharma subsidiary. They are now extremely similar in size and function. Both are likely to remain indispensable in the new healthcare landscape for several years.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- DHR’s TA Score: 4 bullish, 6 bearish.
- TMO’s TA Score: 3 bullish, 7 bearish.
Price Growth
DHR (@Medical Specialties) experienced а -2.28% price change this week, while TMO (@Medical Specialties) price change was -0.73% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
Reported Earning Dates
DHR is expected to report earnings on Jul 28, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| DHR | TMO | DHR / TMO | |
| Capitalization | 127B | 174B | 73% |
| EBITDA | 7.08B | 11.7B | 60% |
| Gain YTD | -21.159 | -18.922 | 112% |
| P/E Ratio | 34.90 | 25.80 | 135% |
| Revenue | 24.8B | 45.2B | 55% |
| Total Cash | 5.7B | 3.26B | 175% |
| Total Debt | 18.5B | 43.2B | 43% |
DHR | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 93 | |
SMR RATING 1..100 | 81 | 62 | |
PRICE GROWTH RATING 1..100 | 58 | 54 | |
P/E GROWTH RATING 1..100 | 65 | 47 | |
SEASONALITY SCORE 1..100 | 26 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (8) in the Medical Specialties industry is in the same range as TMO (12). This means that DHR’s stock grew similarly to TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (93) in the Medical Specialties industry is in the same range as DHR (100). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as DHR (81). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
TMO's Price Growth Rating (54) in the Medical Specialties industry is in the same range as DHR (58). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
TMO's P/E Growth Rating (47) in the Medical Specialties industry is in the same range as DHR (65). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
| DHR | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 58% | 2 days ago 55% |
| Stochastic ODDS (%) | 2 days ago 63% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 57% | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 46% | 2 days ago 62% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 54% | 2 days ago 61% |
| Advances ODDS (%) | 10 days ago 54% | 13 days ago 62% |
| Declines ODDS (%) | 2 days ago 61% | 2 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 53% | 2 days ago 55% |
| Aroon ODDS (%) | 2 days ago 62% | 2 days ago 63% |
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -0.38% | ||
| TMO - DHR | 77% Closely correlated | -1.33% | ||
| A - DHR | 73% Closely correlated | +0.22% | ||
| RGEN - DHR | 68% Closely correlated | -2.06% | ||
| RVTY - DHR | 64% Loosely correlated | -1.83% | ||
| BIO - DHR | 64% Loosely correlated | -2.22% | ||
More | ||||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.